FASN and breast cancer: Because our findings might be explained in terms of FASN-driven maintenance of an undifferentiated state in stem-like cells [44–46] within tumor populations, we evaluated whether therapeutically valuable drugs with a well-known FASN inhibiting activity that are currently available such as the anti-diabetic metformin [47–50] might significantly impact the malignant features of BC stem-like cells.